{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:52:52Z","timestamp":1787028772512,"version":"build-2736575974"},"reference-count":81,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Inflammation is the preceding condition for the development of mild and severe pathological conditions, including various forms of osteopenia, cancer, metabolic syndromes, neurological disorders, atherosclerosis, cardiovascular, lung diseases, etc., in human and animals. The inflammatory status is induced by multifarious intracellular signaling cascades, where cytokines, chemokines, arachidonic acid metabolites, adhesion molecules, immune cells and other components foster a \u201cslow burn\u201d at a local or systemic level. Assuming that countering inflammation limits the development of inflammation-based diseases, a series of new side-effects-free therapies was assessed in experimental and domestic animals. Within the targets of the drug candidates for quenching inflammation, an archetypal autophagic gear, the p62\/sqstm1 protein, has currently earned attention from researchers. Intracellular p62 has been recently coined as a multi-task tool associated with autophagy, bone remodeling, bone marrow integrity, cancer progression, and the maintenance of systemic homeostasis. Accordingly, p62 can act as an effective suppressor of inflamm-aging, reducing oxidative stress and proinflammatory signals. Such an operational schedule renders this protein an effective watchdog for degenerative diseases and cancer development in laboratory and pet animals. This review summarizes the current findings concerning p62 activities as a molecular hub for cell and tissues metabolism and in a variety of inflammatory diseases and other pathological conditions. It also specifically addresses the applications of exogenous p62 (DNA plasmid) as an anti-inflammatory and homeostatic regulator in the treatment of osteoporosis, metabolic syndrome, age-related macular degeneration and cancer in animals, and the possible application of p62 plasmid in other inflammation-associated diseases.<\/jats:p>","DOI":"10.3390\/life12040539","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T16:21:30Z","timestamp":1649262090000},"page":"539","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["P62\/SQSTM1 beyond Autophagy: Physiological Role and Therapeutic Applications in Laboratory and Domestic Animals"],"prefix":"10.3390","volume":"12","author":[{"given":"Maria Giovanna","family":"Sabbieti","sequence":"first","affiliation":[{"name":"School of Biosciences and Veterinary Medicine, University of Camerino, 62032 Camerino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3629-0391","authenticated-orcid":false,"given":"Andrea","family":"Marchegiani","sequence":"additional","affiliation":[{"name":"School of Biosciences and Veterinary Medicine, University of Camerino, 62032 Camerino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert A.","family":"Sufianov","sequence":"additional","affiliation":[{"name":"Federal Center of Neurosurgery, 625032 Tyumen, Russia"},{"name":"Sechenov First Moscow State Medical University, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir L.","family":"Gabai","sequence":"additional","affiliation":[{"name":"CureLab Oncology Inc., Dedham, MA 02026, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Shneider","sequence":"additional","affiliation":[{"name":"CureLab Oncology Inc., Dedham, MA 02026, USA"},{"name":"Department of Molecular Biology, Ariel University, Ariel 40700, Israel"},{"name":"Institute of Biomedical Systems and Biotechnology, Peter the Great St. Petersburg Polytechnic University, 195251 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Agas","sequence":"additional","affiliation":[{"name":"School of Biosciences and Veterinary Medicine, University of Camerino, 62032 Camerino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"key":"ref_1","unstructured":"Kumar, V., Abbas, A.K., Fausto, N., Robbins, S.L., and Cotran, R.S. (2005). Pathologic Basis of Disease, Elsevier Saunders. [7th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"R733","DOI":"10.1016\/j.cub.2012.07.029","article-title":"Evolution of inflammatory diseases","volume":"22","author":"Okin","year":"2012","journal-title":"Curr. Biol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Patil, K.R., Mahajan, U.B., Unger, B.S., Goyal, S.N., Belemkar, S., Surana, S.J., Ojha, S., and Patil, C.R. (2019). Animal Models of Inflammation for Screening of Anti-inflammatory Drugs: Implications for the Discovery and Development of Phytopharmaceuticals. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184367"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ncb2979","article-title":"Cargo recognition and trafficking in selective autophagy","volume":"16","author":"Stolz","year":"2014","journal-title":"Nat. Cell. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41413-019-0058-7","article-title":"Autophagy in bone homeostasis and the onset of osteoporosis","volume":"7","author":"Yin","year":"2019","journal-title":"Bone Res."},{"key":"ref_6","first-page":"397","article-title":"When autophagy meets cancer through p62\/SQSTM1","volume":"2","author":"Puissant","year":"2012","journal-title":"Am. J. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9241","DOI":"10.1073\/pnas.1322913111","article-title":"Regulation of cell proliferation and migration by p62 through stabilization of Twist1","volume":"111","author":"Qiang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Agas, D., and Sabbieti, M.G. (2021). Autophagic Mediators in Bone Marrow Niche Homeostasis. Adv. Exp. Med. Biol., 1\u201315.","DOI":"10.1007\/5584_2021_666"},{"key":"ref_9","first-page":"883","article-title":"Accumulation of p62 is associated with poor prognosis in patients with triple-negative breast cancer","volume":"6","author":"Luo","year":"2013","journal-title":"Onco Targets Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1349-7006.2012.02216.x","article-title":"Accumulation of p62\/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma","volume":"103","author":"Inoue","year":"2012","journal-title":"Cancer Sci."},{"key":"ref_11","first-page":"9889","article-title":"Overexpression of p62 is associated with poor prognosis and aggressive phenotypes in osteosarcoma","volume":"15","author":"Lu","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/j.celrep.2014.11.031","article-title":"p62 is required for stem cell\/progenitor retention through inhibition of IKK\/NF-\u03baB\/Ccl4 signaling at the bone marrow macrophage-osteoblast niche","volume":"9","author":"Chang","year":"2014","journal-title":"Cell Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"16338","DOI":"10.1002\/jcp.28299","article-title":"P62 deficiency shifts mesenchymal\/stromal stem cell commitment toward adipogenesis and disrupts bone marrow homeostasis in aged mice","volume":"234","author":"Lacava","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.18632\/oncotarget.2884","article-title":"Plasmid DNA-coding p62 as a bone effective anti-inflammatory\/anabolic agent","volume":"6","author":"Sabbieti","year":"2015","journal-title":"Oncotarget"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1002\/jcp.29654","article-title":"Loss of p62 impairs bone turnover and inhibits PTH-induced osteogenesis","volume":"235","author":"Agas","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cvsm.2010.05.008","article-title":"Inflammatory Diseases of the Spine in Small Animals","volume":"40","author":"Tipold","year":"2010","journal-title":"Vet. Clin. N. Am. Small Anim. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0300985817739091","article-title":"Pathology and Pathogenesis of Immune-Mediated Diseases of Animals","volume":"55","author":"Diehl","year":"2018","journal-title":"Vet. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1053\/joca.2002.0811","article-title":"Microscopic localization of active gelatinases in equine osteochondritis dissecans (OCD) cartilage","volume":"10","author":"Clegg","year":"2002","journal-title":"Osteoarthr. Cartil."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/nyas.13572","article-title":"Bone quality changes associated with aging and disease: A review","volume":"1410","author":"Boskey","year":"2017","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1177\/1925362118797737","article-title":"Brief Review on Metabolic Bone Disease","volume":"8","author":"Davila","year":"2018","journal-title":"Acad. Forensic Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Bruyette, D.S., Bexfield, N., Chretin, J.D., Kidd, L., Kube, S., Langston, C., Owen, T.J., Oyama, M.A., Peterson, N., and Reiter, L.V. (2020). Canine Hypothyroidism. Clinical Small Animal Internal Medicine, Wiley Online Library. Chapter 9.","DOI":"10.1002\/9781119501237"},{"key":"ref_22","first-page":"193","article-title":"Overview: Animal models of osteopenia and osteoporosis","volume":"3","author":"Jee","year":"2001","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1534-5807(03)00403-9","article-title":"The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis","volume":"6","author":"Duran","year":"2004","journal-title":"Dev. Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1172\/JCI28267","article-title":"Mutation of the sequestosome 1 (p62) gene increases osteoclasto-genesis but does not induce Paget disease","volume":"117","author":"Kurihara","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1093\/hmg\/ddn266","article-title":"A SQSTM1\/p62 mutation linked to Paget\u2019s disease increases the osteoclastogenic potential of the bone microenvironment","volume":"17","author":"Hiruma","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1093\/hmg\/ddr172","article-title":"A point mutation in the ubiquitin-associated domain of SQSMT1 is sufficient to cause a Paget\u2019s disease-like disorder in mice","volume":"20","author":"Daroszewska","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"9530","DOI":"10.1074\/jbc.RA118.002449","article-title":"p62\/sequestosome 1 deficiency accelerates osteoclastogenesis in vitro and leads to Paget\u2019s disease\u2013like bone phenotypes in mice","volume":"293","author":"Zach","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1002\/jcp.30296","article-title":"Archetypal autophagic players through new lenses for bone marrow stem\/mature cells regulation","volume":"236","author":"Agas","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"R176","DOI":"10.1186\/ar3501","article-title":"Quantification of the whole-body burden of radiographic osteoarthritis using factor analysis","volume":"3","author":"Nelson","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/vsu.13282","article-title":"Effects of short- and long-term administration of nonsteroidal anti-inflammatory drugs on osteotomy healing in dogs","volume":"48","author":"Gallaher","year":"2019","journal-title":"Vet. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/fcp.12137","article-title":"Effect of corticosteroids on articular cartilage: Have animal studies said everything?","volume":"29","author":"Vandeweerd","year":"2015","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4142\/jvs.2009.10.3.239","article-title":"The effect of doxycycline on canine hip osteoarthritis: Design of a 6-month clinical trial","volume":"10","author":"Nganvongpanit","year":"2009","journal-title":"J. Vet. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1749-6632.1994.tb24763.x","article-title":"Treatment of canine osteoarthritis with sodium pentosan polysulfate and insulin-like growth factor-1","volume":"732","author":"Rogachefsky","year":"1994","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2460\/javma.256.12.1335","article-title":"Nutrition and nutraceuticals in the changing management of osteoarthritis for dogs and cats","volume":"256","author":"Johnson","year":"2020","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1302\/2046-3758.1010.BJR-2020-0540.R1","article-title":"Clinical outcomes following intra-articular injection of autologous adipose-derived mesenchymal stem cells for the treatment of osteoarthritis in dogs characterized by weight-bearing asymmetry","volume":"10","author":"Black","year":"2021","journal-title":"Bone Jt. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1146\/annurev-immunol-031210-101322","article-title":"Inflammatory mechanisms in obesity","volume":"29","author":"Gregor","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1517\/14728222.2014.991311","article-title":"Adipose tissue macrophages: The inflammatory link between obesity and cancer?","volume":"19","author":"Wagner","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrn2297","article-title":"From inflammation to sickness and depression: When the immune system subjugates the brain","volume":"9","author":"Dantzer","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bbr.2014.08.065","article-title":"Serotonin controlling feeding and satiety","volume":"277","author":"Voigt","year":"2015","journal-title":"Behav. Brain Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/da.22084","article-title":"Cytokine targets in the brain: Impact on neurotransmitters and neurocircuits","volume":"30","author":"Miller","year":"2013","journal-title":"Depress. Anxiety"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejphar.2014.10.031","article-title":"Serotonin: A never-ending story","volume":"753","author":"Olivier","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00702-019-02084-y","article-title":"Animal models of major depression: Drawbacks and challenges","volume":"126","author":"Planchez","year":"2019","journal-title":"J. Neural Transm."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3389\/fpsyg.2014.00925","article-title":"Mood, food, and obesity","volume":"5","author":"Singh","year":"2014","journal-title":"Front. Psychol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"56030","DOI":"10.18632\/oncotarget.19840","article-title":"P62 plasmid can alleviate diet-induced obesity and metabolic dysfunctions","volume":"8","author":"Halenova","year":"2017","journal-title":"Oncotarget"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cmet.2006.01.011","article-title":"Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62","volume":"3","author":"Rodriguez","year":"2006","journal-title":"Cell Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.cell.2015.12.057","article-title":"NF-kB restricts inflammasome activation via elimination of damaged mitochondria","volume":"164","author":"Zhong","year":"2016","journal-title":"Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1242\/dmm.017913","article-title":"Biology and therapy of inherited retinal degenerative disease: Insights from mouse models","volume":"8","author":"Veleri","year":"2015","journal-title":"Dis. Model Mech."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1463-5224.2009.00694.x","article-title":"The use of canine models of inherited retinal degeneration to test novel therapeutic approaches","volume":"12","author":"Beltran","year":"2009","journal-title":"Vet. Ophthalmol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.preteyeres.2017.03.002","article-title":"The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD","volume":"60","author":"Datta","year":"2017","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00018-016-2147-8","article-title":"Inflammation and its role in agerelated macular degeneration","volume":"73","author":"Kauppinen","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-3-319-17121-0_3","article-title":"Biology of p62\/sequestosome-1 in Age-Related Macular Degeneration (AMD)","volume":"854","author":"Wang","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"41533","DOI":"10.1038\/srep41533","article-title":"Contributions of age-related alterations of the retinal pigment epithelium and of glia to the AMD-like pathology in OXYS rats","volume":"7","author":"Telegina","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.18632\/aging.101537","article-title":"p62\/SQSTM1 coding plasmid prevents age related macular degeneration in a rat model","volume":"10","author":"Kolosova","year":"2018","journal-title":"Aging"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tibs.2006.12.002","article-title":"Signal integration and diversification through the p62 scaffold protein","volume":"32","author":"Moscat","year":"2007","journal-title":"Trends Biochem. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1365-2559.2005.02313.x","article-title":"Cytosolic overexpression of p62 sequestosome 1 in neoplastic prostate tissue","volume":"48","author":"Kitamura","year":"2006","journal-title":"Histopathology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1677\/erc.1.01312","article-title":"The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease","volume":"14","author":"Rolland","year":"2007","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.18632\/oncotarget.1397","article-title":"Broad-spectrum anti-tumor and anti-metastatic DNA vaccine based on p62-encoding vector","volume":"4","author":"Venanzi","year":"2013","journal-title":"Oncotarget"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/j.1439-0531.2011.01816.x","article-title":"Canine mammary tumours, an overview","volume":"46","author":"Sleeckx","year":"2011","journal-title":"Reprod. Domest. Anim."},{"key":"ref_59","unstructured":"Vail, D., Thamm, D., and Liptack, J. (2020). Tumors of the mammary gland. Withrow and MacEwen\u2019s Small Animal Clinical Oncology, Elsevier. [6th ed.]."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Salas, Y., M\u00e1rquez, A., Diaz, D., and Romero, L. (2015). Epidemiological study of mammary tumors in female dogs diagnosed during the period 2002-2012: A growing animal health problem. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0127381"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/vr.103398","article-title":"Adjuvant therapy for highly malignant canine mammary tumours: Cox-2 inhibitor versus chemotherapy: A case\u2013control prospective study","volume":"179","author":"Arenas","year":"2016","journal-title":"Vet. Rec."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/vco.12092","article-title":"Surgical treatment of mammary carcinomas in dogs with or without postoperative chemotherapy","volume":"14","author":"Tran","year":"2016","journal-title":"Vet. Comp. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"623800","DOI":"10.3389\/fvets.2021.623800","article-title":"From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review","volume":"8","author":"Valdivia","year":"2021","journal-title":"Front. Vet. Sci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10549-017-4548-2","article-title":"Canine invasive mammary carcinomas as models of human breast cancer. Part 1: Natural history and prognostic factors","volume":"167","author":"Nguyen","year":"2018","journal-title":"Breast Cancer Res.Treat."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nbt.2793","article-title":"Companion therapeutics","volume":"32","author":"Sinha","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"12803","DOI":"10.18632\/oncotarget.2516","article-title":"Pilot study of p62 DNA vaccine in dogs with mammary tumors","volume":"5","author":"Gabai","year":"2014","journal-title":"Oncotarget"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"10711","DOI":"10.18632\/aging.102486","article-title":"p62-DNA-encoding plasmid reverts tumor grade, changes tumor stroma, and enhances anticancer immunity","volume":"11","author":"Venanzi","year":"2019","journal-title":"Aging"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"53730","DOI":"10.18632\/oncotarget.16574","article-title":"Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors","volume":"8","author":"Ponomarenko","year":"2017","journal-title":"Oncotarget"},{"key":"ref_69","first-page":"4","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"8","author":"Hollingsworth","year":"2019","journal-title":"NPJ Vaccines"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"294","DOI":"10.18632\/oncotarget.27323","article-title":"Response of a chemo-resistant triple-negative breast cancer patient to a combination of p62-encoding plasmid, Elenagen, and CMF chemotherapy","volume":"11","author":"Ponomarenko","year":"2020","journal-title":"Oncotarget"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"S457","DOI":"10.1016\/j.annonc.2021.08.561","article-title":"Plasmid encoding p62\/SQSTM1 administered in combination with CMF chemotherapy improves outcomes in metastatic triple-negative breast cancer patients","volume":"32","author":"Krasny","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"S725","DOI":"10.1016\/j.annonc.2021.08.1201","article-title":"Adding dosing of plasmid encoding p62\/SQSTM1 to gemcitabine chemotherapy may provide clinical benefits to patients with platinum-resistant ovarian cancer","volume":"32","author":"Polyakov","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"20140231","DOI":"10.1098\/rstb.2014.0231","article-title":"Comparative oncology: What dogs and other species can teach us about humans with cancer","volume":"370","author":"Schiffman","year":"2015","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41568-020-0297-3","article-title":"Improving human cancer therapy through the evaluation of pet dogs","volume":"20","author":"LeBlanc","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pharmthera.2018.01.012","article-title":"Canine sarcomas as a surrogate for the human disease","volume":"188","author":"Gustafson","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"8951","DOI":"10.1038\/s41598-017-09444-2","article-title":"A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma","volume":"7","author":"Maekawa","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.cvsm.2019.04.010","article-title":"Cancer immunotherapies","volume":"49","author":"Bergman","year":"2019","journal-title":"Vet. Clin. N. Am. Small Anim. Pract."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.vetimm.2015.02.004","article-title":"Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma","volume":"164","author":"Rue","year":"2015","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"11476","DOI":"10.1038\/s41598-020-68470-9","article-title":"Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment","volume":"10","author":"Mizuno","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0300985819900352","article-title":"Generation and validation of an antibody to canine CD19 for diagnostic and future therapeutic purposes","volume":"57","author":"Haran","year":"2020","journal-title":"Vet. Pathol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/vco.12523","article-title":"p62\/SQSTM1 expression in canine mammary tumours: Evolutionary notes","volume":"17","author":"Mariotti","year":"2019","journal-title":"Vet. Comp. Oncol."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/12\/4\/539\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:49:00Z","timestamp":1760136540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/12\/4\/539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,6]]},"references-count":81,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["life12040539"],"URL":"https:\/\/doi.org\/10.3390\/life12040539","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,6]]}}}